<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795570</url>
  </required_header>
  <id_info>
    <org_study_id>RTU_EstenosisUretra_2020_HUVN</org_study_id>
    <nct_id>NCT04795570</nct_id>
  </id_info>
  <brief_title>Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors</brief_title>
  <acronym>STRICT-TURP</acronym>
  <official_title>Hormonal Status and Coagulative Disorders as Risk Factors for Urethral Stricture After Transurethral Resection of the Prostate/Bladder: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biosanitaria de Granada (ibs.Granada)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Virgen de las Nieves</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently no prognostic or predictive risk marker for this urethral stricture&#xD;
      disease.&#xD;
&#xD;
      The most conservative standard treatment for urethral stricture (internal urethrotomy) has a&#xD;
      very high recurrence rate (greater than 75%) and, on many occasions, reconstructive&#xD;
      urologists have to choose within a great variety of further complex interventions. Knowing&#xD;
      risk and predictive markers of this disease could help to optimize both the need and the&#xD;
      approach for these surgeries and may offer a more individualized management to patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological mechanisms that influence the development of urethral stricture are&#xD;
      not established. In developed countries, the most common etiology of urethral stricture is&#xD;
      idiopathic (41%) followed by iatrogenic (35%).&#xD;
&#xD;
      Serum testosterone is important in urethral development, in the integrity of the corpora&#xD;
      cavernosa and has been shown to play a fundamental role in the development of genital&#xD;
      structures. Recently, hypoandrogenism (HA) has been associated with a decrease in urethral&#xD;
      androgen receptors and periurethral vascularization. Furthermore, low serum testosterone&#xD;
      levels appear to be implicated in an increased risk of urethral atrophy.&#xD;
&#xD;
      In recent years it has been proven that coagulation, in addition to influencing the formation&#xD;
      of the provisional matrix, participates in mechanisms of tissue injury through the activation&#xD;
      of PARs. As a result, the coagulation cascade directly influences several key aspects of the&#xD;
      wound healing response, from platelet aggregation and vasoconstriction, but also inflammation&#xD;
      and scar formation. Although it is strictly regulated under normal conditions, an imbalance&#xD;
      in favor of a procoagulant state as occurs in many pathologies of other organs (liver, lung,&#xD;
      kidney) has the potential to deregulate inflammatory and tissue repair mechanisms and&#xD;
      culminate in fibrosis.&#xD;
&#xD;
      In general, it is accepted that the probability of developing a urethral stricture after&#xD;
      endoscopic treatment is around 2-10% of cases. However, this complication has never been&#xD;
      studied in depth and the true incidence of urethral stricture, and its consequences in&#xD;
      quality of life, after a transurethral procedure is unknown.&#xD;
&#xD;
      The aim of this study is to analyze the potential role of serum hormonal status and&#xD;
      coagulation disorders as risk factors for the development of urethral stricture after&#xD;
      transurethral surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of anatomic urethral stricture</measure>
    <time_frame>6 months</time_frame>
    <description>It will be studied in all patients by flexible urethroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of functional urethral stricture</measure>
    <time_frame>6 months</time_frame>
    <description>Studied by uroflowmetry and PROM questionnaries</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hormonal status</measure>
    <time_frame>Within 6 months after TUR P/B</time_frame>
    <description>Determination of serum sexual hormones (Testosterone, estrogens, FSH, LH), TSH, T4 and PRL</description>
  </other_outcome>
  <other_outcome>
    <measure>Coagulation disorders</measure>
    <time_frame>The day before TUR P/B</time_frame>
    <description>Comprehensive profile of procoagulation disorders determined in peripheral blood</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Urethral Stricture, Male</condition>
  <condition>Hormone Deficiency</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cases. Patients who develop urethral stricture</arm_group_label>
    <description>Patients who develop urethral stricture within 6 months after TUR P/B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls. Patients who DO NOT develop urethral stricture</arm_group_label>
    <description>Patients who DO NOT develop urethral stricture within 6 months after TUR P/B</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral resection of the prostate or bladder</intervention_name>
    <description>All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.</description>
    <arm_group_label>Cases. Patients who develop urethral stricture</arm_group_label>
    <arm_group_label>Controls. Patients who DO NOT develop urethral stricture</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing transurethral resection of the prostate or bladder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing transurethral resection of the prostate or bladder (TUR P/B) at&#xD;
             our department.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not giving their informed consent&#xD;
&#xD;
          -  Patients with urethral catheter at the moment of TUR P/B&#xD;
&#xD;
          -  Patients with any type of urethral stricture at the moment of TUR P/B&#xD;
&#xD;
          -  Patients under hormonal treatments (testosterone, thyroxine...) 1 year before the TUR&#xD;
             P/B.&#xD;
&#xD;
          -  Patients with already known coagulation disorders or undergoing anticoagulation&#xD;
             treatments at the moment of the blood test.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Puche-Sanz, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Puche Sanz, MD PhD</last_name>
    <phone>0034 958 020 145</phone>
    <email>ignacio.puche.sspa@juuntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Puche-Sanz, MD, PhD</last_name>
      <phone>0034 958 020 145</phone>
      <email>ignacio.puche.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Almudena Sabio-Bonilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Cristina Jimenez-Dominguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Entrena-Ureña, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Virgen de las Nieves</investigator_affiliation>
    <investigator_full_name>Ignacio Puche Sanz</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Stricture</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

